Opko Health (NASDAQ:OPK) announced its quarterly earnings results on Friday. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03, Briefing.com reports. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. The company had revenue of $250.00 million during the quarter, compared to analyst estimates of $264.04 million. During the same quarter last year, the firm posted ($0.08) earnings per share. The firm’s revenue was up 1.6% on a year-over-year basis.
Opko Health stock traded down $0.40 on Friday, hitting $3.09. 7,341,070 shares of the stock traded hands, compared to its average volume of 3,831,201. The company has a current ratio of 1.05, a quick ratio of 0.90 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $2.16 billion, a P/E ratio of -10.66 and a beta of 1.89. Opko Health has a 1 year low of $2.66 and a 1 year high of $6.40.
In other news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the stock in a transaction on Friday, August 17th. The stock was acquired at an average price of $5.54 per share, with a total value of $55,400.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $17,001,988.54. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have acquired 70,000 shares of company stock valued at $392,950 in the last three months. Insiders own 42.74% of the company’s stock.
A number of brokerages recently commented on OPK. ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a research note on Thursday, July 26th. BidaskClub raised Opko Health from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 24th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price target on shares of Opko Health in a research note on Tuesday, August 7th. Finally, Barrington Research reaffirmed a “buy” rating and issued a $7.00 price target on shares of Opko Health in a research note on Friday, October 5th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $9.69.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
See Also: Diversification Important in Investing
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.